Aequus Pharmaceuticals Inc. (AQS.V)

0.0300 +0.0100 (+50.00%) At close: 03:57PM EDT

Aequus Pharmaceuticals Inc.

200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
Canada
604 336 7906
https://www.aequuspharma.ca

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Description

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Corporate governance

Aequus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.